Versa Vascular, Inc.
PrivateLast Round
Series C
Aug 11, 2026
Est. Valuation
$96M
Total Funding Raised
$69.3M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Versa Vascular, Inc. operates in Healthcare & Life Sciences and is based in Santa Cruz, California. Its latest recorded funding round was a Series C round in August 2026.
Versa Vascular, Inc. is a medical technology company that develops minimally invasive catheter-based implant systems to treat tricuspid valve regurgitation.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Versa Vascular, Inc. Comparables
Compare Versa Vascular, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CroíValve | 89% | |
| VDyne | 88% | |
| Laplace Interventional | 85% |
For institutional investors. Book with your work email.
Versa Vascular, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 11, 2026 | ||||
| Series C | Jul 28, 2025 |
For institutional investors. Book with your work email.
Versa Vascular, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cadence Healthcare Ventures | Series C |
| View Ventures | Series C |
| Santa Cruz Ventures | Series C |
| BioStar Capital | Series C |
| S3 Ventures | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 2, 2026
Open roles increased to 14, representing 67% of headcount.
- Aug 11, 2026
$42M round led by BioStar Capital and S3 Ventures.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingAug 13, 2026
On Aug 13th '26, Versa Vascular announces $42.3M in Series C funding, with additional funds expected to support clinical research on its AdapTR device and further product development.
- hiresAug 13, 2026
Versa Vascular appoints former Medtronic Transcatheter Mitral and Tricuspid Therapies vice president and general manager Bill Shields as CEO in California on Aug 13th '26, replacing retiring David Hovda, who remains an advisor.
For institutional investors. Book with your work email.
Versa Vascular, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Versa Vascular, Inc.'s valuation, stock price, and market status.
Is Versa Vascular, Inc. a public or private company?
Versa Vascular, Inc. is a private company.
What is the current stock price of Versa Vascular, Inc.?
Versa Vascular, Inc. is a private company, so its shares have no public market price. Caplight tracks Versa Vascular, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Versa Vascular, Inc. worth (valuation)?
Versa Vascular, Inc.'s valuation is estimated at $96.0M based on funding round data.
Can I buy Versa Vascular, Inc. stock?
Versa Vascular, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Versa Vascular, Inc.'s last funding round?
Versa Vascular, Inc.'s most recent funding round was Series C on August 11, 2026.
Who are the main investors in Versa Vascular, Inc.?
Key investors in Versa Vascular, Inc. include BioStar Capital, S3 Ventures.
Will Versa Vascular, Inc. IPO soon?
No public IPO plans have been announced for Versa Vascular, Inc..
How can I track Versa Vascular, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Versa Vascular, Inc.'s shares on secondary markets.